|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1650 Diagonal Road |
Address2 |
|
| City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1386-12
|
||||||||
|
6. House ID# 321810000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: James C. Denneny, III |
Date | 10/18/2024 11:05:29 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
7/10/2024: Sign-on letter to Chair and Ranking Member of Senate Committee on Appropriations, Subcommittee on State, Foreign Operations, and Related Programs in support on $10 million for Neglected Surgical Conditions for FY2025. Outlines health and longevity benefits of supporting surgical interventions through low-and-middle-income counties (LMICs).
7/23/2024: Sign-on letter to House Speaker, House Minority Leader, Senate Majority Leader, and Senate Minority Leader in opposition to the Equitable Community Access to Pharmacist Services Act (H.R. 1770/S. 2477); includes issues related to scope of practice, patient care, physician education and training, and the CBO scoring system.
7/24/2024: Sign-on letter to House Speaker, House Minority Leader, Senate Majority Leader, and Senate Minority Leader in support of the Strengthening Medicare for Patients and Providers Act (H.R. 2474), the Provider Reimbursement Stability Act (H.R. 6371), and the Value in Health Care (VALUE) Act (H.R. 5013/S.3503); issues related to the Medicare Access and CHIP Reauthorization Act (MACRA), inflationary updates to the Medicare Physician Fee Schedule, reforms to budget neutrality laws, reforms to MACRA's Merit-based Incentive Payment System (MIPS), and changes to Alternative Payment Models (APMs).
7/29/2024: Letter to Reps. Burgess, Cardenas, Griffith, and Gonzalez in support of the Physician Led and Rural Access to Quality Care Act (H.R. 9001); issues related to patient access to care, healthcare innovation and competition, and physician ownership of healthcare facilities.
8/21/2024: Coalition letter to Director of the Division of Services for Children with Special Health Needs at the Maternal and Child Health Bureau of the HRSA regarding changes to the funding structure of state Early Hearing Detection Intervention (EHDI) programs. Letter urges Director to ensure new structure ensures continued excellence and supports stated aims to improve children lost to follow-up (LTF) in these programs, screen three-year-olds, utilize new gene therapies, meet existing benchmark for referrals, and other quality metrics.
9/4/2024: Letter to Sens. Boozman, Welch, Tillis, King, Marshall, and Shaheen in support of the Physician Fee Stabilization Act (S. 4935); issues related to the Medicare Physician Fee Schedule and the Medicare Economic Index.
9/10/2024: Sign-on letter to House Speaker, House Minority Leader, Senate Majority Leader, and Senate Minority Leader in support of the Strengthening Medicare for Patients and Providers Act (H.R. 2474), the Provider Reimbursement Stability Act (H.R. 6371), and the Physician Fee Stabilization Act (S. 4935); issues related to the Medicare physician payment system and inflationary impacts on the Medicare Physician Fee Schedule.
9/13/2024: Sign-on letter to Congress in support of the Physician Led and Rural Access to Quality Care Act (H.R. 9001); issues related to physician ownership of hospitals in needy areas and rural access to quality healthcare services.
Issues related to hearing healthcare, in general.
Issues pertaining to health information technology and electronic health records, in general.
Issues pertaining to Graduate Medical Education, in general.
Issues pertaining to healthcare liability reform, in general.
Issues pertaining to prior authorization, the Improving Seniors Timely Access to Care Act (S. 4532 /H.R. 8702), and in general.
Issues pertaining to Medicare physician reimbursement, related to the Strengthening Medicare for Patients and Providers Act (H.R. 2474) and the Preserving Seniors Access to Physicians Act of 2023 (H.R. 6683), and in general.
Issues pertaining to Medicare allergy verification, the Penicillin Allergy Verification and Evaluation Act of 2024 (H.R. 9778), and in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
7/24/2024: Sign-on letter to House Speaker, House Minority Leader, Senate Majority Leader, and Senate Minority Leader in support of the Strengthening Medicare for Patients and Providers Act (H.R. 2474), the Provider Reimbursement Stability Act (H.R. 6371), and the Value in Health Care (VALUE) Act (H.R. 5013/S.3503); issues related to the Medicare Access and CHIP Reauthorization Act (MACRA), inflationary updates to the Medicare Physician Fee Schedule, reforms to budget neutrality laws, reforms to MACRA's Merit-based Incentive Payment System (MIPS), and changes to Alternative Payment Models (APMs).
9/4/2024: Letter to Sens. Boozman, Welch, Tillis, King, Marshall, and Shaheen in support of the Physician Fee Stabilization Act (S. 4935); issues related to the Medicare Physician Fee Schedule and the Medicare Economic Index.
9/10/2024: Sign-on letter to House Speaker, House Minority Leader, Senate Majority Leader, and Senate Minority Leader in support of the Strengthening Medicare for Patients and Providers Act (H.R. 2474), the Provider Reimbursement Stability Act (H.R. 6371), and the Physician Fee Stabilization Act (S. 4935); issues related to the Medicare physician payment system and inflationary impacts on the Medicare Physician Fee Schedule.
Issues pertaining to Medicare allergy verification, the Penicillin Allergy Verification and Evaluation Act of 2024 (H.R. 9778), and in general.
Issues related to hearing healthcare, in general.
Issues pertaining to step therapy, in general.
Issues pertaining to health information technology and electronic health records, in general.
Issues pertaining to Graduate Medical Education, in general.
Issues pertaining to healthcare liability reform, in general
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues pertaining to tobacco control, including the pending FDA rule on prohibiting menthol cigarettes, and in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
7/10/2024: Sign-on letter to Chair and Ranking Member of Senate Committee on Appropriations, Subcommittee on State, Foreign Operations, and Related Programs in support on $10 million for Neglected Surgical Conditions for FY2025. Outlines health and longevity benefits of supporting surgical interventions through low-and-middle-income counties (LMICs).
7/23/2024: Sign-on letter to House Speaker, House Minority Leader, Senate Majority Leader, and Senate Minority Leader in opposition to the Equitable Community Access to Pharmacist Services Act (H.R. 1770/S. 2477); includes issues related to scope of practice, patient care, physician education and training, and the CBO scoring system.
7/24/2024:Sign-on letter to House Speaker, House Minority Leader, Senate Majority Leader, and Senate Minority Leader in support of the Strengthening Medicare for Patients and Providers Act (H.R. 2474), the Provider Reimbursement Stability Act (H.R. 6371), and the Value in Health Care (VALUE) Act (H.R. 5013/S.3503); issues related to the Medicare Access and CHIP Reauthorization Act (MACRA), inflationary updates to the Medicare Physician Fee Schedule, reforms to budget neutrality laws, reforms to MACRA's Merit-based Incentive Payment System (MIPS), and changes to Alternative Payment Models (APMs).
9/4/2024: Letter to Sens. Boozman, Welch, Tillis, King, Marshall, and Shaheen in support of the Physician Fee Stabilization Act (S. 4935); issues related to the Medicare Physician Fee Schedule and the Medicare Economic Index.
9/10/2024: Sign-on letter to House Speaker, House Minority Leader, Senate Majority Leader, and Senate Minority Leader in support of the Strengthening Medicare for Patients and Providers Act (H.R. 2474), the Provider Reimbursement Stability Act (H.R. 6371), and the Physician Fee Stabilization Act (S. 4935); issues related to the Medicare physician payment system and inflationary impacts on the Medicare Physician Fee Schedule.
Issues pertaining to Medicare allergy verification, the Penicillin Allergy Verification and Evaluation Act of 2024 (H.R. 9778), and in general.
Issues pertaining to the budget and appropriations, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Issues pertaining to healthcare practice and the Federal Supremacy Clause at the Department of Veterans Affairs, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |